this from the Wilson report is a sad commentary really.
"GSK is still ignoring the retail channel for Relenza. The most recent IMS Health data reports ~10-15 thousand US Relenza prescriptions, monthly."
If so why? perhaps cause they dont have capacity yet
- Forums
- ASX - By Stock
- BTA
- strange???
strange???, page-7
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online